Last reviewed 2026-05-29 · How we verify

Quadruple Allopathic therapy

Hafiz Muhammad Asif · Phase 2 active Small molecule ✓ Verified May 2026

Quadruple Allopathic therapy is a Small molecule drug developed by Hafiz Muhammad Asif. It is currently in Phase 2 development. Also known as: Omeprazol, Amoxicillin, Metronodazole, TRITEC (ranitidine bismuth citrate).

Quadruple Allopathic therapy is a treatment approach studied for its effectiveness in treating Helicobacter Pylori infections, as seen in clinical trials such as NCT02004197. The therapy involves a combination of allopathic interventions, but the specific mechanisms and components are not explicitly stated in the provided facts.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Quadruple Allopathic therapy
Also known as	Omeprazol, Amoxicillin, Metronodazole, TRITEC (ranitidine bismuth citrate)
Sponsor	Hafiz Muhammad Asif
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Quadruple and Phytomedicine-based Therapies in H. Pylori Infection (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Quadruple Allopathic therapy CI brief — competitive landscape report
Quadruple Allopathic therapy updates RSS · CI watch RSS
Hafiz Muhammad Asif portfolio CI

Frequently asked questions about Quadruple Allopathic therapy

What is Quadruple Allopathic therapy?

Quadruple Allopathic therapy is a Small molecule drug developed by Hafiz Muhammad Asif.

Who makes Quadruple Allopathic therapy?

Quadruple Allopathic therapy is developed by Hafiz Muhammad Asif (see full Hafiz Muhammad Asif pipeline at /company/hafiz-muhammad-asif).

Is Quadruple Allopathic therapy also known as anything else?

Quadruple Allopathic therapy is also known as Omeprazol, Amoxicillin, Metronodazole, TRITEC (ranitidine bismuth citrate).

What development phase is Quadruple Allopathic therapy in?

Quadruple Allopathic therapy is in Phase 2.

Manufacturer: Hafiz Muhammad Asif — full pipeline
Also known as: Omeprazol, Amoxicillin, Metronodazole, TRITEC (ranitidine bismuth citrate)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing